MAMATHA CHIVUKULA,MD,FASCP (@chivukulamd) 's Twitter Profile
MAMATHA CHIVUKULA,MD,FASCP

@chivukulamd

“Making life better for others than yourself “ Passions - my work and my running

ID: 832741993532968960

linkhttps://www.facebook.com/First-International-Breast-Cancer-Symposium-2013 calendar_today18-02-2017 00:02:17

369 Tweet

219 Followers

278 Following

Swikrity U Baskota,MD, FCAP (@baskotacytopath) 's Twitter Profile Photo

A4: Recent abstract from AACR about proficiency assessment of HER2-low scoring using different assays aacrjournals.org/cancerres/arti… #HER2low #PathTwitter #BreastPath

A4: Recent abstract from AACR about proficiency assessment of HER2-low scoring using different assays
aacrjournals.org/cancerres/arti…
#HER2low #PathTwitter #BreastPath
Swikrity U Baskota,MD, FCAP (@baskotacytopath) 's Twitter Profile Photo

A4: Another comparison of HercepTest and Pathway 4B5: more tumors were overscored as IHC 2 + by HercepTest link.springer.com/article/10.100… #HER2low #PathTwitter #BreastPath

A4: Another comparison of HercepTest and Pathway 4B5: more tumors were overscored as IHC 2 + by HercepTest
link.springer.com/article/10.100…
#HER2low #PathTwitter #BreastPath
Dr. Bui Pathologist🌼 (@drbuipathology) 's Twitter Profile Photo

A4. We did a survey study to identify the most commonly used antibodies, 4B5 came on top, which is the only FDA approved companion diagnostic indicated to identify HER2-low status in patients with metastatic breast cancer. #HER2low #PathTwitter #BreastPath

MAMATHA CHIVUKULA,MD,FASCP (@chivukulamd) 's Twitter Profile Photo

#HER2low Daisy trail results presented at SABCS2022 and investigators found T-Dxd has clinically meaningful activity in HER2 positive, HER2low and HER2 zero advanced breast cancer,#breast path

Dr. Bui Pathologist🌼 (@drbuipathology) 's Twitter Profile Photo

There are differences in QIA approach. Some analyze areas of interest. Some analyze the whole tumor area. Some algorithm trained to adjust the HER2 FISH data.